Video Monitoring and Payments to Help People Finish Latent Tuberculosis Treatment
Tests video-observed dosing with payments to help adults with latent tuberculosis finish treatment.
Key facts
- Who runs it
- Johns Hopkins University
- Where
- Baltimore, United StatesSee the site
- Trial code
- Registry title
- Economic Incentives and vDOT for Latent Tuberculosis Infection
- Status
- Recruiting
- People taking part
- 399 people, planned
- Started
- 7 Feb 2022
- Expected to end
- 1 Dec 2027
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Usual Care
- Video Directly Observed Therapy alone
- Video Directly Observed Therapy plus Financial Incentives
- Record updated
- 4 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in the Baltimore area who are starting treatment for latent tuberculosis (TB infection without active disease). It tests video-observed treatment with and without financial incentives.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Latent tuberculosis, with the clinician agreeing that treatment is appropriate. Active TB is not allowed.
- Earlier treatment
- Must be prescribed 3 months of Isoniazid/Rifapentine, 3 months of Isoniazid/Rifampin, or 4 months of Rifampin.
Main reasons for not taking part
- Younger than 18 years
- Active TB
- Prescribed a different treatment plan for latent TB
- Pregnant women
- No translated consent form available in the person's spoken language
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- 18 years old or older,
- diagnosed with latent TB and determined to be appropriate for latent TB treatment by participants clinicians
- reside in Baltimore metro area
- speaks English or Spanish, or a language for which there is a short form available via the Johns Hopkins Medicine Institutional Review Board
- prescribed 3 months Isoniazid/Rifapentine, prescribed 3 months Isoniazid/Rifampin, or 4 months Rifampin
Who cannot take part
- younger than 18 years old
- pregnant women (as determined by non-study directed clinical evaluation; BCHD performs urine pregnancy testing on women of child bearing age when indicated)
- diagnosed with active TB
- prescribed an alternative treatment regimen for latent TB
- participant's spoken language does not have a translated long or short consent form
Where in United States
- Baltimore City Health Department, and Baltimore metropolitan area clinics and health departmentsBaltimore, United StatesContact: Principal InvestigatorTaking people
About the trial
What the trial wants to find out
The purpose of this study is to evaluate a novel and scalable intervention that combines Video Directly Observed Therapy (vDOT) and financial incentives to promote completion of treatment for latent tuberculosis. Adult participants who are initiating treatment for latent tuberculosis will be recruited from the Baltimore City Health Department. The primary hypothesis is that the incentive intervention will increase the percentage of participants that complete the treatment for latent tuberculosis above the completion rates of participants receiving usual care.
The 3 groups in the trial
- Usual CareExisting treatment, for comparison
Participants will receive routine (non-study directed) medical care for latent tuberculosis infection according to published guidelines, including medication, nurse case management, Tuberculosis health education, and toxicity assessments.
- Video Directly Observed Therapy aloneExisting treatment, for comparison
Participants in this group will receive the same treatments and education provided to Usual Care Control participants, however treatment will be viewed by video directly observed therapy (video-DOT)
Treatment: Usual Care and Video Directly Observed Therapy alone
- Video Directly Observed Therapy plus Financial IncentivesTreatment being tested
Participants in this group will receive the same treatments and education provided to Usual Care Control participants, as well as treatment viewed by video DOT. This arm will also earn financial contingent incentives. Participants will receive incentive payments when a submitted video is monitored by a staff member and deemed valid. If a participant fails to submit a video on a medication day or if a submitted video is deemed invalid (i.e., not the correct person or no appropriate ingestion of medication), the participant will not receive the scheduled incentive amount that day and the daily incentive value will be decreased.The participant will have opportunities the next day to again resume adherence. After taking the medication again for one week, participants will earn a reduced incentive until they adhere to the medication schedule for a week.
Treatment: Usual Care, Video Directly Observed Therapy alone, and Video Directly Observed Therapy plus Financial Incentives
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Economic Incentives and Video Directly Observed Therapy to Promote Adherence to Latent Tuberculosis Infection
- Plain-language title
- Video Monitoring and Payments to Help People Finish Latent Tuberculosis TreatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 4 May 2026